*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 22, 2026 (the "**Prospectus**") of Jiangxi Institute of Biological Products Inc. (江西生物製品研究所股份有限公司) (the "**Company**").*

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the laws of Hong Kong).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the "**U.S. Securities Act**") or securities law of any state or other jurisdiction of the United States. The securities may not be offered, sold, pledged or otherwise transferred within the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

Jiangxi Institute of Biological Products Inc.
江西生物製品研究所股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6915)

STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF OVER-ALLOTMENT OPTION

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilization period in connection with the Global Offering ended on July 25, 2026, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Further information on stabilizing actions undertaken by China International Capital Corporation Hong Kong Securities Limited, as Stabilizing Manager, its affiliates, or any person acting for it during the stabilization period is set out in this announcement.

LAPSE OF OVER-ALLOTMENT OPTION

The Overall Coordinators did not exercise the Over-allotment Option during the stabilization period and the Over-allotment Option lapsed on July 25, 2026. Accordingly, no H Shares were or will be issued under the Over-allotment Option.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilization period in connection with the Global Offering ended on Saturday, July 25, 2026, being the 30th day after the last day for lodging of applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by China International Capital Corporation Hong Kong Securities Limited, as Stabilizing Manager or its affiliates or any person acting for it, during the stabilization period were:

(1) the over-allocations of an aggregate of 5,435,000 H Shares in the International Offering, representing approximately 15.0% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option); and

(2) successive purchases of an aggregate of 5,435,000 H Shares in the price range of HK$7.40 to HK$10.46 per H Share (excluding brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%) on the market during the stabilization period, representing approximately 15.0% of the total number of the Offer Shares available under the Global Offering before any exercise of the Over-allotment Option, to be delivered to the placees who have agreed to delayed delivery of the relevant H Shares subscribed by them under the Global Offering.

The last purchase made by the Stabilizing Manager or its affiliates or any person acting for it, on the market during the course of the stabilization period was on June 30, 2026 at the price of HK$9.78 per H Share (excluding brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%).

LAPSE OF OVER-ALLOTMENT OPTION

The Overall Coordinators (for themselves and on behalf of the International Underwriters) did not exercise the Over-allotment Option during the stabilization period, and the Over-allotment Option lapsed on Saturday, July 25, 2026. Accordingly, no H Shares were or will be issued under the Over-allotment Option.

PUBLIC FLOAT

Immediately after the end of the stabilization period, the Company complies and will continue to comply with the public float requirements pursuant to Rule 19A.13A(1) of the Listing Rules.

By order of the Board
Jiangxi Institute of Biological Products Inc.
Ms. JING Yue
Chairperson of the Board

Hong Kong, July 26, 2026

As of the date of this announcement, the Board of Directors of the Company comprises: (i) Ms. JING Yue, Mr. YAO Xiaodong, Mr. LI Changqing, and Ms. JING Ruihua as executive Directors; (ii) Ms. YU Ailian and Mr. XIAO Changqing as non-executive Directors; and (iii) Dr. ZOU Pingxue, Dr. TSANG Hiu Leong, and Mr. WU Di as independent non-executive Directors.